APA Citatie

Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., . . . Springer, C. (2021). The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann Oncol.

Chicago Style citaat

Saturno, G., et al. "The Paradox-breaking PanRAF Plus SRC Family Kinase Inhibitor, CCT3833, Is Effective in Mutant KRAS-driven Cancers." Ann Oncol 2021.

MLA citatie

Saturno, G., et al. "The Paradox-breaking PanRAF Plus SRC Family Kinase Inhibitor, CCT3833, Is Effective in Mutant KRAS-driven Cancers." Ann Oncol 2021.